Navigation Links
ProUroCare Medical Secures $885,000 in Financing

MINNEAPOLIS, June 17 /PRNewswire-FirstCall/ -- ProUroCare Medical, Inc. (OTC Bulletin Board: PUMD), a provider of proprietary imaging products, today announced that it has closed on a $885,000 private placement of debt financing.  The funding was provided by a small group of existing investors closely aligned with the company.  

The proceeds from the financing will be used to fund manufacturing and marketing scale-up activities, expand the company's existing intellectual property portfolio and form a scientific advisory board.  A portion of the funding will also be used to pay existing debt obligations and for general corporate purposes.

"This additional funding brings the total amount raised by the company since 2007 to more than $9.3 million," said CEO Rick Carlson.  "We are very pleased by the support that we continue to receive from investors for the ProUroScan™ prostate imaging system and the market opportunities that exist for this technology.  Our immediate focus is to ensure the successful processing of our de novo filing and the resulting FDA clearance for commercialization."

About ProUroCare Medical, Inc.

ProUroCare Medical, Inc. is a publicly traded company engaged in the business of developing innovative medical imaging products. The company's current focus is the ProUroScan prostate imaging system, which is used to document abnormalities of the prostate detected by a Digital Rectal Exam (DRE).  Based in Minneapolis, Minn., ProUroCare is quoted on the OTCBB.

Safe Harbor Statement

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of ProUroCare's future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause ProUroCare's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability of ProUroCare to find adequate financing to complete the development of its products; the high level of secured and unsecured debt incurred by ProUroCare; the dependence by ProUroCare on third parties for the development and manufacture of its products; and other risks and uncertainties detailed from time to time in ProUroCare's filings with the Securities and Exchange Commission including its most recently filed Form 10-K and Form 10-Q. ProUroCare undertakes no duty to update any of these forward-looking statements.

SOURCE ProUroCare Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ProUroCare to Showcase Investigational Portable Platform for Its Prostate Imaging Device at AUA 2010
2. ProUroCare Medical Announces Filing of Request to Classify the Prostate Mechanical Imager ("PMI") as a Class II Device
3. ProUroCare Medical Elects Two New Directors
4. ProUroCare Medical Completes Multiple Site Clinical Study for Imaging Prostate Abnormalities
5. ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology
6. ProUroCare Medical Inc. Announces Pricing of Equity Offering
7. Bacterin International Secures Three-Year Agreement to Distribute Biologic Products to Broadlanes Network of Over 6,000 Medical Facilities
8. Simbionix Welcomes Two New Members to Expand Compays Medical Education Product Offerings
9. Varian Medical Systems Equips International Oncologys First Comprehensive Cancer Center in India
10. Obamas Healthcare Reform Bill and its Impact on the U.S. Healthcare Markets (Pharmaceuticals, Medical Devices and Health Insurance)
11. Halt Medical, Inc. Receives FDA Clearance
Post Your Comments:
(Date:12/1/2015)... 1, 2015   MabVax Therapeutics Holdings, Inc . ... it has filed an Investigational New Drug Application (IND) ... the Company,s lead fully human antibody product HuMab 5B1 ... plans to initiate the Phase I clinical trial early ... --> The planned Phase I trial will evaluate ...
(Date:12/1/2015)... , Dec. 1, 2015   Craneware, Inc ... cycle solutions, today announced the company will showcase ... ChargeLink ® solution at the American ... Clinical Meeting . The new features are focused ... of monitoring and managing enterprise-wide pharmacy charges to ...
(Date:12/1/2015)... , Dec. 01, 2015 ... of the "Medical Alert Systems/Personal Emergency Response ... by Geography - Global Forecas" report to ... announced the addition of the "Medical Alert ... by End-User and by Geography - Global Forecas" ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 2015 , ... The Multiple System Atrophy Coalition has announced the launch of ... (MSA) research, timed today to coincide with Giving Tuesday 2015, a global day of ... to work and be productive, to do simple daily activities like walking to the ...
(Date:12/1/2015)... ME (PRWEB) , ... December 01, 2015 , ... Royal ... reports a new study that found post-menopausal women who took the nutritional supplement creatine, ... than women who trained but did not take creatine. , The report is part ...
(Date:12/1/2015)... Fla. (PRWEB) , ... December 01, 2015 , ... ... number of leadless pacemakers in the U.S. and is the only hospital in ... from the largest clinical data presentation of transcatheter pacing patients were revealed recently ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, ... expansion of the company’s growing product line of food safety and seafood fraud ... Sockeye (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable species identification for ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic ... United States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a ... catastrophic contributors to diseases of the diabetic foot. The American Board of ...
Breaking Medicine News(10 mins):